"Xinhua Zhu, MD, PhD, is a medical oncologist and hematologist at Monter Cancer Center, where he specializes in treating genitourinary cancer, including cancer of the prostate, kidney, bladder and testicles. He focuses on compassionate, evidence-based care, rooted in his research background.""My research helps me think outside the box when creating treatment plans. Dr. Zhu is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Michael Herman is an Urologist in Rockville Centre, New York. Dr. Herman is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Obstructive Uropathy, Urinary Tract Infection in Children, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery.

Alvin Goh is an Urologist in Uniondale, New York. Dr. Goh is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Congenital Giant Megaureter, Cystectomy, and Nephrectomy. Dr. Goh is currently accepting new patients.

Massimiliano Spaliviero is an Urologist in Uniondale, New York. Dr. Spaliviero is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Enlarged Prostate (BPH), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Rohit Jain is an Oncologist and a Hematologist Oncology provider in Flushing, New York. Dr. Jain is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Penectomy, and Endoscopy. Dr. Jain is currently accepting new patients.

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Joph Steckel is an Urologist in Lake Success, New York. Dr. Steckel is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery.

As Senior Vice President of the Urology Service Line, Chair of theSmith Institute for Urology, and Chair of Urology at the Zucker Schoolof Medicine at Hofstra/Northwell, Samir Taneja, MD will establish hisclinical practice at Lenox Hill Hospital and Long Island Jewish MedicalCenter focused on the surgical management of prostate cancerand renal tumors. He is an expert in urologic oncology, renowned fortransforming the field of prostate cancer diagnosis and treatmentby improving methods of prostate imaging, cancer detection, anddisease localization. Having performed thousands of robotic, ablative,laparoscopic and open surgical procedures, his specific clinical focushas been in improving prostate cancer patient outcomes throughpioneering techniques for focal ablative therapy, refining surgicaltechniques for robotic prostatectomy and partial nephrectomy,devising accelerated recovery pathways for robotic prostatectomy/partial nephrectomy, and providing muti-modal surgical approachesfor patients with high risk and recurrent prostate cancer. As leader ofthe department, he will strive to ensure individualized care of urologicdisease through state-of-the-art surgical approaches and multi-disciplinary care.Prior to joining Northwell, Dr Taneja was a faculty member of NYUGrossman School of Medicine for 29-years as a tenured professorof urology, radiology, and biomedical engineering. Most recently heserved as Director of the Division of Urologic Oncology and ViceChair in the Department of Urology at NYU Langone Health, as well asGenitourinary Program Leader in the Perlmutter Cancer Center.Dr. Taneja has conducted extensive clinical research on the use ofimaging in prostate cancer and is considered a pioneer in the use ofMRI to diagnose and localize prostate cancer and the emerging field ofprostate cancer focal therapy. He has authored more than 250 articles,30 book chapters, and six textbooks and monographs on urologiccancer and surgery. He is the editor of Taneja's Complications ofUrologic Surgery: Prevention and Diagnosis, one of the most widely readtextbooks in American Urology. Dr. Taneja is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Louis Kavoussi, MD, MBA, Director of teleintervention at Northwell. He is a world-renowned urologic surgeon who brings more than 30 years of specialized expertise in minimally invasive urological surgery. His area of focus includes treating a wide range of urologic diseases, including kidney obstructions, renal stones and urologic cancer. At the forefront of innovation, Dr. Kavoussi pioneered several new surgical techniques, including the first minimally invasive approaches to kidney surgery for kidney cancer and kidney donation. He was also part of the team that performed the first laparoscopic prostate removal for cancer. In 1999, Dr. Kavoussi received a Smithsonian Computerworld Permanent Collection award for his work in developing telerounding, the starting point of telehealth medicine-to facilitate physician communication with hospitalized patients. Before joining Northwell in 2005 as chair of urology, Dr. Kavoussi completed his medical degree at the State University of New York at Buffalo. He obtained his urologic training at Washington University of St. Louis and, directly following residency, was named chief of urology at the Jewish Hospital of St. Louis. In 1991, he was appointed assistant professor at Harvard School of Medicine and director of endourology at the Brigham and Women's Hospital. In 1993, he joined the faculty of Johns Hopkins University School of Medicine, where he was vice chairman of urology and named a Patrick C. Walsh Distinguished Professor. Dr. Kavoussi values a team approach to care, and often collaborates with other specialists to create personalized and comprehensive treatment plans. His patients appreciate his easygoing personality and thoughtfulness. As the Waldbaum-Gardner Distinguished Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dr. Kavoussi is passionate about training the next generation of surgeons. He has presented his work and given live surgical demonstrations at conferences around the world and has more than 500 academic publications. Dr. Kavoussi is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

Kenneth Angelino is a Hematologist and an Oncologist in Rockville Centre, New York. Dr. Angelino is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Thrombocytopenia, Anemia, Vulvar Cancer, and Angiosarcoma.

Richard Lee is a Hematologist Oncology specialist and a Hematologist in Rockville Centre, New York. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Inflammatory Breast Cancer, Thrombocytopenia, Paget Disease of the Breast, and Myelodysplastic Syndrome (MDS).

Valerie Kremer is a Hematologist in Rockville Centre, New York. Dr. Kremer is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Thrombocytopenia, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and ALK-Positive Non-Small Cell Lung Cancer.

Raymond Sultan is an Urologist in Rockville Centre, New York. Dr. Sultan is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Bilateral Hydronephrosis, Ureteroscopy, and Prostatectomy.

Eric Thall is an Urologist in Rockville Centre, New York. Dr. Thall is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Obstructive Uropathy, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery.

Steven Harris is an Urologist in Oceanside, New York. Dr. Harris is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Obstructive Uropathy, and Ureteroscopy.

Shashi Shah is an Urologist in Lynbrook, New York. Dr. Shah is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Bilateral Hydronephrosis, Obstructive Uropathy, Prostatectomy, and Pancreaticoduodenectomy.

Eric Shoenfeld is a primary care provider, practicing in Family Medicine in Valley Stream, New York. Dr. Shoenfeld is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are High Cholesterol, Hypertension, Familial Hypertension, and Glucocorticoid-Remediable Aldosteronism.

Robert Nejat is an Urologist in Garden City, New York. Dr. Nejat is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, and Ureteroscopy.

Mario Lacouture is a Dermatologist in Garden City, New York. Dr. Lacouture is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Autosomal Recessive Hypotrichosis, Hartsfield Syndrome, Alopecia Areata, and Basal Cell Skin Cancer.

Robert Moldwin, MD, FACS is Director of the Pelvic Pain Center at The Arthur Smith Institute for Urology and serves as physician-in-charge of Urologic Infectious/Inflammatory Diseases. He is Professor of Urology at the Hofstra North Shore-LIJ School of Medicine.A world-renowned leader in the field of pelvic pain, Dr. Moldwin has special interests in varied pain syndromes of the bladder and pelvis. His other clinical and research interests range from urinary incontinence to infectious diseases of the urinary tract. Dr. Moldwin is published in peer-reviewed journals including Cancer, The Journal of Urology, The British Journal of Urology International, The British Medical Journal, Contemporary Urology and Urology. Dr. Moldwin is an expert consultant, lecturing to audiences of physicians, patients, and members of the media on issues such as incontinence, urological health, interstitial cystitis, and pelvic disorders. He currently serves on multiple medical advisory boards, including the Interstitial Cystitis Association, and has been a member of their Board of Directors for over a decade.Dr Moldwin is affiliated with numerous medical societies including the American Urological Association, International Association for the Study of Pain and The Society for Female Urology and Urodynamics. He is past president of the Society for Infections and Inflammation in Urology. He was also co-chairperson for the recently completed Multidisciplinary Approaches to the Study of Chronic Urologic Pelvic Pain (MAPP), a research initiative sponsored by the National Institutes of Health. Dr Moldwin is currently a committee reviewer for the American Urological Association IC/BPS Guidelines and serves as Vice-President for the International Society for the Study of Interstitial Cystitis/Bladder Pain Syndrome (ESSIC).After earning his medical degree at the University of Chicago Pritzker School of Medicine, Dr. Moldwin completed his general surgical training and urology residency at the Long Island Jewish Medical Center. He also served as a Valentine Fellow through the New York Academy of Medicine, studying infectious and inflammatory urological diseases in the Department of Urology at Thomas Jefferson Medical College in Philadelphia. Dr. Moldwin is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Interstitial Cystitis, Frequent or Urgent Urination, Bacterial Prostatitis, and Vulvodynia.